| Business Summary | | Alfacell
Corporation
is
a
development
stage
company
engaged
in
the
discovery,
investigation
and
development
of
a
new
class
of
anti-cancer
drugs
from
amphibian
ribonucleases.
Ribonucleases
degrade
ribonucleic
acids
causing
an
interruption
in
protein
synthesis
resulting
in
the
inhibition
of
cell
growth
and
induction
of
apoptosis
(programmed
cell
death).
Its
first
product
under
development
is
ONCONASE,
which
targets
a
variety
of
cancers,
most
of
which
are
known
to
become
resistant
to
other
chemotherapeutic
drugs. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Alfacell
Corporation
is
a
development
stage
biopharmaceutical
company
primarily
engaged
in
the
discovery
and
development
of
a
new
class
of
anti-cancer
drugs
from
amphibian
ribonucleases.
For
the
nine
months
ended
4/30/01,
revenues
fell
79%
to
$8
thousand.
Net
loss
rose
7%
to
$1.5
million.
Revenues
reflect
lower
balances
of
cash
and
cash
equivalents.
Higher
loss
reflects
higher
general,
administrative
and
interest
expenses
and
a
decrease
of
$304
thousand
in
tax
benefits. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Kuslima Shogen, 55 CEO,
Chairman and Acting Chief Financial Officer | $154K | Stanislaw Mikulski, M.D., 56 Exec.
VP and Medical Director | 134K | Dollar amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|